ES2103815T3 - Suspensiones oftalmicas. - Google Patents

Suspensiones oftalmicas.

Info

Publication number
ES2103815T3
ES2103815T3 ES91912359T ES91912359T ES2103815T3 ES 2103815 T3 ES2103815 T3 ES 2103815T3 ES 91912359 T ES91912359 T ES 91912359T ES 91912359 T ES91912359 T ES 91912359T ES 2103815 T3 ES2103815 T3 ES 2103815T3
Authority
ES
Spain
Prior art keywords
suspension
weight
eye
ophthalmic medicament
mosm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912359T
Other languages
English (en)
Inventor
Jeffery P Davis
Santosh Kumar Chandraskaran
Yansheng Dormitory Building Su
Roy D Archibald
Joseph R Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24172504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Application granted granted Critical
Publication of ES2103815T3 publication Critical patent/ES2103815T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LOS POLIMEROS LIGERAMENTE ENLAZADOS, PREFERIBLEMENTE LOS QUE SE PREPARAN MEDIANTE POLIMERIZACION DE SUSPENSION O EMULSION DE AL MENOS UN 90% DE UN MONOMERO MONOETILENICAMENTE INSATURADO QUE CONTENGA CARBOXIL TAL COMO EL ACIDO ACRILICO CON ENTRE EL 0.1 Y 5% DE UN AGENTE ENLAZADOR POLIFUNCIONAL, Y PREFERIBLEMENTE DIFUNCIONAL, TAL COMO EL GLICOL DE DIVINIL, QUE TENGA UN TAMAÑO DE PARTICULA NO MAYOR A 50 (MU)M EN UN DIAMETRO ESFERICO EQUIVALENTE, CUANDO SE FORMULAN CON UN MEDICAMENTO OFTALMOLOGICO, EN SUSPENSION EN UN MEDIO ACUOSO EN EL QUE LA CANTIDAD DE POLIMERO OSCILA ENTRE UN 0.1 Y UN 6.5%, EN BASE AL PESO TOTAL DE LA SUSPENSION ACUOSA, EL PH SE ENCUENTRA ENTRE EL 3.0 Y 6.5, Y LA PRESION OSMOTICA ES DE ENTRE 10 OSM Y 400 OSM, SUMINISTRAN NUEVOS SISTEMAS DE LIBERACION DE MEDICAMENTOS OFTALMOLOGICOS QUE TENGAN VISCOSIDADES ADECUADAMENTE BAJAS QUE PERMITEN QUE SEAN FACILMENTE ADMINISTRADOS EN EL OJO EN FORMA DE GOTAS.
ES91912359T 1990-06-27 1991-06-25 Suspensiones oftalmicas. Expired - Lifetime ES2103815T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/544,518 US5192535A (en) 1988-02-08 1990-06-27 Ophthalmic suspensions

Publications (1)

Publication Number Publication Date
ES2103815T3 true ES2103815T3 (es) 1997-10-01

Family

ID=24172504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912359T Expired - Lifetime ES2103815T3 (es) 1990-06-27 1991-06-25 Suspensiones oftalmicas.

Country Status (13)

Country Link
US (1) US5192535A (es)
EP (1) EP0536255B1 (es)
JP (1) JP3237118B2 (es)
AT (1) ATE152907T1 (es)
AU (1) AU8103991A (es)
CA (1) CA2086121C (es)
DE (1) DE69126134T2 (es)
DK (1) DK0536255T3 (es)
ES (1) ES2103815T3 (es)
GR (1) GR3023915T3 (es)
NZ (1) NZ238756A (es)
WO (1) WO1992000044A1 (es)
ZA (1) ZA914971B (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
DE69123248T2 (de) * 1991-03-27 1997-03-13 Senju Pharma Co Verfahren zur herstellung einer wässrigen suspension
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
EP0659077A1 (en) * 1992-07-02 1995-06-28 TheraTech, Inc. Controlled release pilocarpine delivery system
US5661171A (en) * 1992-07-02 1997-08-26 Oramed, Inc. Controlled release pilocarpine delivery system
CA2101126A1 (en) * 1992-08-03 1994-02-04 Yasushi Morita Preparation for local treatment
JPH08510597A (ja) * 1993-01-21 1996-11-05 マヨ ファウンデーション フォー メディカル エデュケイション アンド リサーチ 微粒子スイッチング素子
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5654006A (en) * 1993-02-12 1997-08-05 Mayo Foundation For Medical Education And Research Condensed-phase microparticle composition and method
US5753261A (en) * 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
EP0664699A1 (en) * 1993-08-13 1995-08-02 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
JPH10500148A (ja) 1994-03-04 1998-01-06 ユニバーシティ オブ ワシントン ブロック及びグラフトコポリマー並びにそれに関連する方法
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US6309630B1 (en) 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5827835A (en) * 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
US5606043A (en) 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5849879A (en) * 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
US6099558A (en) * 1995-10-10 2000-08-08 Edwards Lifesciences Corp. Intraluminal grafting of a bifuricated artery
US5968068A (en) * 1996-09-12 1999-10-19 Baxter International Inc. Endovascular delivery system
US5814655A (en) * 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) * 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
ATE391492T1 (de) * 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
US6277365B1 (en) 1997-09-18 2001-08-21 Bausch & Lomb Incorporated Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
AU1388999A (en) * 1997-12-16 1999-07-05 Alcon Laboratories, Inc. The use of nitric oxide generations for the treatment of dry eye disorders
WO1999038472A2 (en) * 1998-01-28 1999-08-05 Seatrace Pharmaceuticals Inc Topical vasodilatory gel composition and methods of use and production
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6699492B2 (en) 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6685958B2 (en) 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
JP2003513046A (ja) 1999-11-01 2003-04-08 アルコン，インコーポレイテッド フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
HUP0001769A2 (hu) * 2000-05-04 2002-01-28 dr. Kahán Ilona Molnárné Lakrofil készítmény alkalmazása gyógyászati hatóanyag-tartalmú szemcseppekben
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU2001270593A1 (en) 2000-07-28 2002-02-13 Alcon Universal Ltd. Pharmaceutical compositions containing tobramycin and xanthan gum
ES2396598T3 (es) * 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
US20070098813A1 (en) * 2000-11-08 2007-05-03 Fxs Ventures, Llc Ophthalmic and contact lens solutions with a peroxide source and a preservative
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
JP4084997B2 (ja) * 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
DE60135572D1 (de) * 2000-11-08 2008-10-09 Fxs Ventures Llc Verbesserte ophthalmologische und kontaktlinsenlösungen mit einer peroxidquelle und einem kationischen polymeren konservierungsmittel
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
US20030099294A1 (en) * 2001-11-27 2003-05-29 Limin Wang Picture level adaptive frame/field coding for digital video content
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
CA2483265A1 (en) * 2002-04-25 2003-11-06 Clyde L. Schultz Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20030211173A1 (en) * 2002-05-08 2003-11-13 Veach Tom C. Lubrication composition
RU2005102604A (ru) * 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) Композиция гиалуроновой кислоты и способы применения
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2004091438A2 (en) * 2003-04-15 2004-10-28 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
KR101091461B1 (ko) 2003-11-07 2011-12-07 센주 세이야꾸 가부시키가이샤 프로스타글란딘 함유 의약 조성물
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
ATE504328T1 (de) 2004-11-18 2011-04-15 3M Innovative Properties Co Mikronadelanordungsapplikator und halter
BRPI0517749A (pt) 2004-11-18 2008-10-21 3M Innovative Properties Co dispositivo de aplicação para aplicar um dispositivo de micro-agulha a uma superfìcie de pele, e, método para usar um dispositivo de aplicação
JP5015787B2 (ja) 2004-11-18 2012-08-29 スリーエム イノベイティブ プロパティズ カンパニー マイクロニードルアレイの接触コーティング法
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
EP1827564B1 (en) * 2004-11-18 2015-07-29 3M Innovative Properties Company Masking method for coating a microneedle array
US7236693B2 (en) 2005-03-22 2007-06-26 Globaltec Fireplaces, Inc. Flame simulator for use in an electric heater
WO2006104760A2 (en) * 2005-03-25 2006-10-05 Allergan, Inc. OPHTHALMIC COMPOSITIONS COMPRISING dDC
CA2631497C (en) * 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
WO2007124411A1 (en) * 2006-04-20 2007-11-01 3M Innovative Properties Company Device for applying a microneedle array
EP2023721A2 (en) * 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
WO2009135135A2 (en) * 2008-05-01 2009-11-05 Chia Soo Fibromodulin formulation for reducing corneal scarring
BRPI0912985A2 (pt) * 2008-05-19 2015-10-13 Alcon Res Ltd composições farmacêuticas com polímero de carboxivinila e polímero de povidona
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
US20170128481A9 (en) 2009-03-06 2017-05-11 Insite Vision Corporation Ocular treatment with reduced intraocular pressure
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
WO2011057209A1 (en) * 2009-11-06 2011-05-12 Qlt, Inc. Acidic ophthalmic formulations
KR101543613B1 (ko) 2009-12-03 2015-08-11 알콘 리서치, 리미티드 카복시비닐 폴리머를 포함하는 나노입자 현탁액
USD640554S1 (en) 2010-06-30 2011-06-28 Inspire Pharmaceuticals, Inc. Medicine dispenser
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
EP2758031A1 (en) 2011-09-22 2014-07-30 Bausch & Lomb Incorporated Ophthalmic gel compositions
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2787969B1 (en) 2011-12-07 2021-09-29 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
MX2015002208A (es) 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
US9950002B2 (en) 2013-09-16 2018-04-24 Regents Of The University Of Minnesota Nanoparticles/theranostic vehicles
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
EP3328389A1 (en) 2015-07-27 2018-06-06 Catacore, Inc. Compositions for the treatment of cataracts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
GB2013084B (en) * 1978-01-25 1982-07-28 Alcon Lab Inc Ophthalmic drug dosage
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
EP0145714A1 (en) * 1983-05-25 1985-06-26 Alcon Laboratories, Inc. Ophthalmic gel
WO1984004681A1 (en) * 1983-05-25 1984-12-06 Alcon Lab Inc Ophthalmic solution
ATE151286T1 (de) * 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4820737A (en) * 1987-02-17 1989-04-11 University Of Iowa Research Foundation Lacrimal secretion stimulant (lss)
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions

Also Published As

Publication number Publication date
ZA914971B (en) 1992-09-30
DK0536255T3 (da) 1997-08-25
CA2086121A1 (en) 1991-12-28
DE69126134T2 (de) 1997-10-09
CA2086121C (en) 2001-11-20
NZ238756A (en) 1992-11-25
EP0536255A4 (en) 1993-07-07
JPH05508641A (ja) 1993-12-02
JP3237118B2 (ja) 2001-12-10
GR3023915T3 (en) 1997-09-30
EP0536255A1 (en) 1993-04-14
ATE152907T1 (de) 1997-05-15
AU8103991A (en) 1992-01-23
WO1992000044A1 (en) 1992-01-09
DE69126134D1 (de) 1997-06-19
US5192535A (en) 1993-03-09
EP0536255B1 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
DK0536255T3 (da) Oftalmiske suspensioner
DE68907545D1 (de) Ophthalmische suspensionen.
CA2086120A1 (en) Topical ophthalmic suspensions
DE69424275D1 (de) Alkalische ophthalmische suspensionen
CA2181715A1 (en) Liquid ophthalmic sustained release delivery system
DE3484165D1 (de) Vernetzte poroese polymere fuer eine kontrollierte wirkstoffabgabe.
BR9711403A (pt) Composição e método de bloqueio para uso em formação subterrânea.
BR9206278A (pt) Processo para produzir uma dispersão,dispersão de gotículas e partículas de polímero
KR920011478A (ko) 안과용 미소구
MX9207548A (es) Suspensiones oftalmicas topicas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 536255

Country of ref document: ES